Forest Labs Settles Investor Suits Over $25B Actavis Deal
Forest Laboratories Inc. said Thursday that it had hatched a settlement to end shareholder class actions accusing the board of the Carl Icahn-backed drugmaker of selling the company too cheaply to...To view the full article, register now.
Already a subscriber? Click here to view full article